/LCTX
LCTX Stock - Lineage Cell Therapeutics, Inc.
Healthcare|BiotechnologyAMEX
$1.68-4.00%
$0.07 (-4.00%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.73
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.49
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.85
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LCTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.66 – $1.70
TARGET (TP)$1.93
STOP LOSS$1.55
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.78
52W High$2.09
52W Low$0.37
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.50M | $8.95M | $14.70M | $3.90M | $773,000 |
| Gross Profit | $9.16M | $8.27M | $13.97M | $2.47M | $388,000 |
| Gross Margin | 96.5% | 92.5% | 95.0% | 63.4% | 50.2% |
| Operating Income | $-21,478,000 | $-24,733,000 | $-22,520,000 | $-49,211,000 | $-26,447,000 |
| Net Income | $-18,609,000 | $-21,486,000 | $-26,273,000 | $-43,019,000 | $-20,649,000 |
| Net Margin | -195.9% | -240.2% | -178.7% | -1104.2% | -2671.3% |
| EPS | $-0.09 | $-0.12 | $-0.15 | $-0.26 | $-0.14 |
Company Overview
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$4
Average Target
↑ 157.9% Upside
Now
$4
Low
$4
Average
$5
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 20th 2024 | Craig Hallum | Initiation | Buy | $4 |
| November 2nd 2022 | Robert W. Baird | Initiation | Outperform | $5 |
| June 14th 2022 | B. Riley Securities | Initiation | Buy | $4 |
Earnings History & Surprises
LCTXBeat Rate
17%
Last 18 quarters
Avg Surprise
-47.9%
EPS vs Estimate
Beats / Misses
3/13
2 met exactly
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
+57.1%
$-0.03vs$-0.07
Q2 24
-4.4%
$-0.04vs$-0.04
Q3 24
-34.8%
$-0.03vs$-0.02
Q4 24
-53.5%
$-0.02vs$-0.01
Q1 25
+75.0%
$-0.01vs$-0.04
Q2 25
0.0%
$-0.02vs$-0.02
Q3 25
+50.0%
$-0.01vs$-0.02
Q4 25
-550.0%
$-0.13vs$-0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | $-0.07 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.02 | $-0.13 | -550.0% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.02 | $-0.01 | +50.0% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.02 | $-0.02 | 0.0% | = MET |
Q1 2025 | Mar 10, 2025 | $-0.04 | $-0.01 | +75.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.01 | $-0.02 | -53.5% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.02 | $-0.03 | -34.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.04 | $-0.04 | -4.4% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.07 | $-0.03 | +57.1% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.04 | $-0.04 | -6.7% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.02 | $-0.03 | -32.3% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.02 | $-0.03 | -21.8% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.03 | $-0.03 | -19.2% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.04 | $-0.04 | -14.3% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.04 | $-0.04 | -6.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.03 | $-0.04 | -17.6% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.01 | $-0.05 | -264.2% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.05 | $-0.05 | 0.0% | = MET |
Q3 2021 | Aug 12, 2021 | $-0.03 | $-0.03 | -18.2% | ✗ MISS |
Latest News
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
📈 PositiveBenzinga•Nov 25, 2025, 12:58 PM
HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
📈 PositiveBenzinga•Nov 24, 2025, 05:20 PM
Lineage Cell Therapeutics Sold 12M Common Shares To Janus Henderson Investors At A Purchase Price Of $1.75/Share In A Block Transaction Under Its ATM Offering Program; Company Received $21M In Gross Proceeds
📈 PositiveBenzinga•Nov 12, 2025, 02:29 PM•Also:
Lineage Cell Therapeutics shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 7, 2025, 02:17 PM
Lineage Cell Therapeutics Q3 EPS $(0.13) Misses $(0.02) Estimate, Sales $3.681M Beat $2.300M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 09:01 PM
Lineage Cell Therapeutics Announces Launch Of A New Islet Cell Transplant Program Targeting Type 1 Diabetes
📈 PositiveBenzinga•Sep 8, 2025, 12:01 PM
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
📈 PositiveBenzinga•Aug 27, 2025, 12:17 PM
Lineage Cell Revenue Doubles in Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 01:54 AM
Frequently Asked Questions about LCTX
What is LCTX's current stock price?
Lineage Cell Therapeutics, Inc. (LCTX) is currently trading at $1.68 per share. The stock has moved -4.00% today.
What is the analyst price target for LCTX?
No analyst price targets are currently available for this stock.
What sector is Lineage Cell Therapeutics, Inc. in?
Lineage Cell Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is LCTX's market cap?
Lineage Cell Therapeutics, Inc. has a market capitalization of $0.39 billion, making it a small-cap company.
Does LCTX pay dividends?
No, Lineage Cell Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
AUTL
Autolus Therapeutics plc
$1.63
Mkt Cap: $0.4B
BNTC
Benitec Biopharma Inc.
$11.50
Mkt Cap: $0.3B
FULC
Fulcrum Therapeutics, Inc.
$12.28
Mkt Cap: $0.7B
GALT
Galectin Therapeutics Inc.
$4.38
Mkt Cap: $0.3B
NGNE
Neurogene Inc.
$20.55
Mkt Cap: $0.3B
OCGN
Ocugen, Inc.
$1.40
Mkt Cap: $0.4B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
PRTC
PureTech Health plc
$16.78
Mkt Cap: $0.4B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
Explore stocks similar to LCTX for comparison